




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7A

**Figure 7B**






Figure 8



Lane	Sample	Lane	Sample
1	1Kb ladder	9	LB B, generation 5
2	100ng reference pGG55	10	LB A, generation 9
3	LB A, generation 5	11	LB B, generation 14
4	LB A, generation 9	12	LB B, generation 19*
5	LB A, generation 14	13	LB B, generation 24*
6	LB A, generation 19	14	LB B, generation 29*
7	LB A, generation 24	15	1Kb ladder
8	LB A, generation 29		


* Residual ethanol remaining in sample, therefore the majority of the sample did not load into the well, resulting in a less intense plasmid band

Figure 9A



Lane	Sample	Lane	Sample
1	1Kb ladder	5	TB, generation 21
2	100ng reference pGG55	6	TB, generation 28
3	TB, generation 7	7	TB, generation 35
4	TB, generation 14	8	TB, generation 42

Figure 9B






Figure 10




Figure 11

12/22





Figure 12


Lovaxin_C_pGG55	ADV451 →	CCAAACCCCTACAAAACAAGTTTCATACAGCCTAGCTAAATTTAAIGTTT
Reference_10403S_pFA		CCAAACCCCTACAAAACAAGTTTCATACAGCCTAGCTAAATTTAAATGAATT
Lovaxin_C_pGG55	ADV452 →	*****
Reference_10403S_pFA		TTTCGATTACGGGAAGCTTGGCTCTATTTCGGGTCAACCTTTTAAICCTG
Lovaxin_C_pGG55		TTTCGATTACGGGAAGCTTGGCTCTATTTCGGGTCAACCTTTTAAICCTG
Reference_10403S_pFA		ACCTATGTGTGTAIGGTAAAGAACTCCTGATGGCATCAAGATTACACTGGA
Lovaxin_C_pGG55		ACCTATGTGTGTAIGGTAAAGAACTCCTGATGGCATCAAGATTACACTGGA
Reference_10403S_pFA		*****
Lovaxin_C_pGG55		TAATTTAACAAATGCAGGAGTTAGGATATTCAAGTGGCATCGCACATAGCT
Reference_10403S_pFA		TAATTTAACAAATGCAGGAGTTAGGATATTCAAGTGGCATCGCACATAGCT
Lovaxin_C_pGG55		*****
Reference_10403S_pFA		CAGCTGTAGCAGAAATTATTTCCAAATTAAAGCAAGAGAAAGTTATCGTG
Lovaxin_C_pGG55		CAGCTGTAGCAGAAATTATTTCCAAATTAAAGCAAGAGAAAGTTATCGTG
Reference_10403S_pFA		*****
Lovaxin_C_pGG55		TATAAAATTCATGCTTTTATGTACAAATCGTGATTATCTCAAAAGATA
Reference_10403S_pFA		TATAAAATTCATGCTTTTATGTACAAATCTTGATTATCTCAAAAGATA
Lovaxin_C_pGG55		*****
Reference_10403S_pFA		TGCCCCCTAAATTAGATGAATGGTTTATTAGCAIGTCCTGCTACTTGGG
Lovaxin_C_pGG55		TGCCCCCTAAATTAGATGAATGGTTTATTAGCAIGTCCTGCTACTTGGG
Reference_10403S_pFA		*****
Lovaxin_C_pGG55		*****
Reference_10403S_pFA		GAAAAATTAAATTAA (SEQ ID NO: 31)
Lovaxin_C_pGG55		GAAAAATTAAATTAA (SEQ ID NO: 32)
Reference_10403S_pFA		*****

Figure 13




1. 5 ng of pGG55 D133V;
2. 1 ng of pGG55 D133V;
3. 0.2 ng of pGG55 D133V;
4. 5 ng of pGG55 wild-type;
5. 1 ng of pGG55 wild-type;
6. 0.2 ng of pGG55 wild-type;

Figure 14



- 1) 5 ng of pGG55 D133V;
- 2) 1 ng of pGG55 D133V;
- 3) 0.2 ng of pGG55 D133V;
- 4) 5 ng of pGG55 wild-type;
- 5) 1 ng of pGG55 wild-type;
- 6) 0.2 ng of pGG55 wild-type;

Figure 15



1. 1 ng of pGG55 D133V
2. 1 ng of pGG55 wild-type
3. 100 pg of pGG55 wild-type (10^{-1})
4. 10 pg of pGG55 wild-type (10^{-2})
5. 1 pg of pGG55 wild-type (10^{-3})
6. 100 fg of pGG55 wild-type (10^{-4})
7. 10 fg of pGG55 wild-type (10^{-5})
8. 1 fg of pGG55 wild-type (10^{-6})

Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22

ADXS-HPV with mitomycin/5-FU/RT
For Locally Advanced Anal Cancer




FIGURE 23




FIGURE 24